Ozempic-maker Novo Nordisk slims down to 'Novo' / Photo: Michal Cizek - AFP
-
Turkish Energy Minister Highlights Qatar as Key Partner for Regional and Global Energy Security
-
Rene Eyre Revisits Autobiographical Performance 'Say A Little Prayer' in London
-
London Museum Granted 24/7 License Ahead of November Opening
-
UAE's HCT Holds Record Graduation and Announces Major Training Expansion
-
Dana White Confirms Flight to Washington for Trump Meeting on Press Secretary Role
-
NASA Awards $10B Lunar Contract Framework to SpaceX, Blue Origin
-
Dengue Fever Expands Into High Himalayas as Climate Change Warms Nepal
-
Katy Perry Tells Fans Ex-Husband Russell Brand 'Should Be in Jail' During UK Concert
-
IoT Refrigerator Hacks Disrupt Blood Labs and Supermarkets Across Europe and US
-
South African election results renew debate over identity-based voting
-
Post-election pressures complicate US and Israeli decisions on Iran
-
South African voters report smoother local election but declining IEC trust
-
UN members approve talks on treaty protocol against environmental crime
-
Dolly Parton museum and Nashville hotel open after singer’s death
-
Family-run West Sussex beach café prepares for first winter season
-
George and Amal Clooney attend New York political-comedy reading
-
CT scans reveal health and burial clues from Egypt’s Braided Lady mummy
-
British buyers pay substantial premiums for period-home appearance
-
Oxford faces complaints over lecturer’s classroom attire
-
Thomas Markle released to house arrest after child-abuse-image charge
-
Kyren Wilson and John Higgins reach International Championship snooker final
Ozempic-maker Novo Nordisk slims down to 'Novo'
Danish pharmaceuticals giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Monday a name change to just Novo, hoping it will be more "memorable and relevant" for clients.
The rebrand comes ahead of a strategic presentation on September 21, when executives are to lay out their plan for "a faster, more competitive and increasingly consumer-driven market".
The company is battling fierce competition in the anti-obesity sector, where its hugely successful Ozempic and Wegovy treatments have spurred rivals to catch up.
It released a new tablet form of Wegovy in the United States in January, and the pill was recently approved for use in Europe.
It will keep the full Novo Nordisk as its legal corporate name, using Novo and an updated version of its bull logo for its packaging.
Chief executive Mike Doustdar told Denmark's TV2 television the rebrand was part of an effort to "reinvent the company".
"People who use insulin are only considered as patients," he said.
"But over the past four or five years, we've seen the emergence of a bigger and bigger group that tells us, 'I'm not a patient, I'm not sick. I just want to lose weight'."
A.P.Maia--PC
